News from renalytixai A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 16, 2020, 07:00 ET RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update

Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical...


Jul 13, 2020, 08:57 ET RenalytixAI Announces Launch of Global Offering and Application to List on the Nasdaq Global Market

Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney...


Jul 08, 2020, 08:30 ET RenalytixAI Announces Partnership with America's Choice Provider Network for Coverage Expansion

Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney...


Jul 01, 2020, 11:25 ET RenalytixAI Announces KidneyIntelX Validation Study Accepted for Publication in American Society of Nephrology Journal Kidney360

Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney...


Jun 30, 2020, 13:18 ET RenalytixAI Announces Partnership with the University of Michigan to Extend KidneyIntelX™ Use to Broad CKD Populations and Data Sharing Agreement with a Top Ten Global Pharmaceutical Company

Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney...


Jun 25, 2020, 08:57 ET RenalytixAI Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual-listing and Global Offering

Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney...


Jun 12, 2020, 08:00 ET KidneyIntelX™ Receives New York State Approval to Commence Commercial Testing

Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney...


May 18, 2020, 13:22 ET Renalytix AI Announces Proposed Dual-listing on Nasdaq

Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical...


Apr 27, 2020, 15:44 ET RenalytixAI Utah Commercial Laboratory Facility Achieves ISO 13485 Certification

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced...


Apr 20, 2020, 07:30 ET KidneyIntelX™ to Predict Major Adverse Kidney Events in COVID-19 Patients

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces...


Mar 24, 2020, 08:00 ET RenalytixAI Announces Podium Presentation and Publication on "Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression"

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces...


Mar 02, 2020, 14:11 ET RenalytixAI CEO to Speak at the 40th Annual Cowen Health Care Conference

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting ...


Dec 03, 2019, 12:03 ET Medicare Sets National Price for KidneyIntelX™

Renalytix AI plc (LSE: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the...


Oct 17, 2019, 07:00 ET RenalytixAI Partners with Capital District Physicians' Health Plan, Inc. on KidneyIntelX™

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Capital District ...


Oct 14, 2019, 08:48 ET Johns Hopkins Director of Nephrology Chirag Parikh Joins RenalytixAI Board

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the appointment ...


Jul 29, 2019, 08:35 ET RenalytixAI Appoints Thomas McLain as President and Chief Commercial Officer

Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the expansion of its...


Jul 09, 2019, 08:30 ET RenalytixAI Releases Positive Interim Results in Expanded Validation Study for KidneyIntelX™

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today positive...


Jul 01, 2019, 08:30 ET U.S. CPT® Code Granted for KidneyIntelX™

Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the...


Jun 07, 2019, 08:00 ET Study Published in Journal of Clinical Investigation Insight Demonstrates Ability to Predict Early Rejection in Kidney Transplant with FractalDx Portfolio Technology

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that positive...


May 21, 2019, 08:06 ET RenalytixAI Expands Core Investigator Group for Kidney Transplant Advanced Diagnostic Program

Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the expansion...


May 07, 2019, 08:05 ET RenalytixAI and University Medical Center Groningen to Evaluate KidneyIntelX™ for Early Identification and Guiding Therapeutic Treatment of Diabetic Kidney Disease

Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration ...


May 02, 2019, 08:00 ET FDA Grants Breakthrough Device Designation to KidneyIntelX™

Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has...


Mar 22, 2019, 08:05 ET RenalytixAI Forms Core Investigator Group for Kidney Transplant Advanced Diagnostic Program

Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the formation...


Feb 13, 2019, 07:00 ET RenalytixAI and AKESOgen In Joint Venture Partnership for Expanded Testing Capacity and Pharma Services

RenalytixAI (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the completion of a joint...


Feb 06, 2019, 07:00 ET RenalytixAI Expands Leadership Team to Support Launch of AI-Enabled Diagnostics for Kidney Disease

Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the expansion of its...